Cytomegalovirus retinitis

Expert Review of Ophthalmology

Volumn 2, Issue 4, 2007, Pages 583-595

  Thorne, Jennifer E ^a   Galor, Anat ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; complications; cytomegalovirus retinitis; HAART; progression; vision loss

Indexed keywords

EID: 80053993183     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.4.583     Document Type: Article

References (138)

1. Polis M. Cytomegalovirus disease. In: AIDS Therapy. Dolin R, Masur H, Saag M (Eds). Churchill Livingstone Inc., PA, USA 582–603 (2002).
2. Rowe WP, Hartley JW, Waterman S, Turner HC, Huebner RJ. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc. Soc. Exp. Biol. Med. 92 (2), 418–424 (1956).
3. Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc. Soc. Exp. Biol. Med. 92 (2), 424–430 (1956).
4. Pottage J, Kessler H. Herpes simplex virus infections. In: AIDS Therapy. Dolin R, Masur H, Saag M (Eds). Churchill Livingstone Inc., PA, USA 555–563 (2002).
5. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91 (1), 119–126 (1997).
6. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J. Immunol. 151 (9), 4455–4464 (1993).
7. Stewart JA, Reef SE, Pellett PE, Corey L, Whitley RJ. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21 (Suppl. 1), S114 –S120 (1995).
8. Hoover DR, Saah AJ, Bacellar H et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N. Engl. J. Med. 329 (26), 1922–1926 (1993).
9. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. 124 (7), 633–642 (1996).
10. Jabs DA. Ocular manifestations of HIV infection. Trans. Am. Ophthalmol. Soc. 93, 623–683 (1995).
11. Hoover DR, Peng Y, Saah A et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch. Ophthalmol. 114 (7), 821–827 (1996).
12. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J. Infect. Dis. 166 (6), 1223–1227 (1992).
13. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 5 (11), 1069–1074 (1992).
14. + T-lymphocyte counts. N. Engl. J. Med. 333 (10), 670 (1995).
15. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am. J. Ophthalmol. 115 (5), 575–582 (1993).
16. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group. Arch. Ophthalmol. 107 (12), 1759–1766 (1989).
17. Pathanapitoon K, Ausayakhun S, Kunavisarut P, Pungrasame A, Sirirungsi W. Detection of cytomegalovirus in vitreous, aqueous and conjunctiva by polymerase chain reaction (PCR). J. Med. Assoc. Thai. 88 (2), 228–232 (2005).
18. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 107 (1), 75–80 (1989).
19. Jabs DA. AIDS and ophthalmology in 2004. Arch. Ophthalmol. 122 (7), 1040–1042 (2004).
20. Jabs DA, Van Natta ML, Thorne JE et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology 111 (12), 2224–2231 (2004).
21. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch. Ophthalmol. 114 (1), 23–33 (1996).
22. Freeman WR, Henderly DE, Wan WL et al. Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis. Am. J. Ophthalmol. 103 (4), 527–536 (1987).
23. Kempen JH, Jabs DA, Dunn JP, West SK, Tonascia J. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch. Ophthalmol. 119 (1), 33–40 (2001).
24. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet–Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 101 (7), 1250–1261 (1994).
25. Jabs DA, Enger C, Haller J, de Bustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch. Ophthalmol. 109 (6), 794–799 (1991).
26. Freeman WR, Friedberg DN, Berry C et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am. J. Ophthalmol. 116 (6), 713–720 (1993).
27. The Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet–Ganciclovir Cytomegalovirus Retinitis Trial. Am. J. Ophthalmol. 124 (1), 61–70 (1997).
28. Freeman WR, Quiceno JI, Crapotta JA, Listhaus A, Munguia D, Aguilar MF. Surgical repair of rhegmatogenous retinal detachment in immunosuppressed patients with cytomegalovirus retinitis. Ophthalmology 99 (3), 466–474 (1992).
29. Lim JI, Enger C, Haller JA et al. Improved visual results after surgical repair of cytomegalovirus-related retinal detachments. Ophthalmology 101 (2), 264–269 (1994).
30. Tanna AP, Kempen JH, Dunn JP, Haller JA, Jabs DA. Incidence and management of cataract after retinal detachment repair with silicone oil in immune compromised patients with cytomegalovirus retinitis. Am. J. Ophthalmol. 136 (6), 1009–1015 (2003).
31. McCluskey P, Grigg J, Playfair TJ. Retinal detachments in patients with AIDS and CMV retinopathy: a role for laser photocoagulation. Br. J. Ophthalmol. 79 (2), 153–156 (1995).
32. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. AIDS 14 (11), 1571–1581 (2000).
33. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch. Ophthalmol. 121 (1), 99–107 (2003).
34. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am. J. Ophthalmol. 124 (2), 227–233 (1997).
35. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 (13), 853–860 (1998).
36. Holtzer CD, Jacobson MA, Hadley WK et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994–1997. AIDS 12 (14), 1931–1933 (1998).
37. Wohl DA, Pedersen S, van der Horst CM. Routine ophthalmologic screening for cytomegalovirus retinitis in patients with AIDS. J. Acquir. Immune Defic. Syndr. 23 (5), 438–439 (2000).
38. Jabs DA, Van Natta ML, Kempen JH et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am. J. Ophthalmol. 133 (1), 48–61 (2002).
39. Deayton JR, Wilson P, Sabin CA et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 14 (9), 1163–1170 (2000).
40. Jabs DA, Van Natta ML, Thorne JE et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology 111 (12), 2232–2239 (2004).
41. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin. Infect. Dis. 37 (10), 1365–1373 (2003).
42. Walsh JC, Jones CD, Barnes EA, Gazzard BG, Mitchell SM. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 12 (6), 613–618 (1998).
43. Jabs DA, Holbrook JT, Van Natta ML et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 112 (5), 771–779 (2005).
44. Freeman WR. Retinal detachment in cytomegalovirus retinitis: should our approach be changed? Retina 19 (4), 271–273 (1999).
45. Jabs D, Thorne J. Ophthalmologic disease. In: AIDS Therapy. Dolin R, Masur H, Saag M (Eds). Churchill-Livingstone, PA, USA 785–800 (2002).
46. Canzano JC, Morse LS, Wendel RT. Surgical repair of cytomegalovirus-related retinal detachment without silicone oil in patients with AIDS. Retina 19 (4), 274–280 (1999).
47. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia JA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch. Ophthalmol. 121 (4), 466–476 (2003).
48. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 113 (8), 1432–1440 (2006).
49. Thorne JE, Holbrook JT, Jabs DA, Kempen JH, Nichols C, Meinert CL. Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology 114 (3), 591–598 (2007).
50. Robinson MR, Reed G, Csaky KG, Polis MA, Whitcup SM. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am. J. Ophthalmol. 130 (1), 49–56 (2000).
51. Zegans ME, Walton RC, Holland GN, O’Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 125 (3), 292–300 (1998).
52. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am. J. Ophthalmol. 129 (5), 634–639 (2000).
53. Karavellas MP, Plummer DJ, Macdonald JC et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179 (3), 697–700 (1999).
54. Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch. Ophthalmol. 116 (2), 169–175 (1998).
55. Karavellas MP, Song M, Macdonald JC, Freeman WR. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am. J. Ophthalmol. 130 (1), 57–64 (2000).
56. Karavellas MP, Azen SP, MacDonald JC et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 21 (1), 1–9 (2001).
57. Wright ME, Suzman DL, Csaky KG, Masur H, Polis MA, Robinson MR. Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis. Clin. Infect. Dis. 36 (8), 1063–1066 (2003).
58. Goldberg DE, Freeman WR. Uveitic angle closure glaucoma in a patient with inactive cytomegalovirus retinitis and immune recovery uveitis. Ophthalmic Surg. Lasers 33 (5), 421–425 (2002).
59. Song MK, Azen SP, Buley A et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am. J. Ophthalmol. 136 (4), 696–702 (2003).
60. Goldberg DE, Wang H, Azen SP, Freeman WR. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br. J. Ophthalmol. 87 (7), 853–855 (2003).
61. Kempen JH, Min YI, Freeman WR et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 113 (4), 684–694 (2006).
62. Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 23 (4), 495–502 (2003).
63. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br. J. Ophthalmol. 83 (5), 540–545 (1999).
64. Kosobucki BR, Goldberg DE, Bessho K et al. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am. J. Ophthalmol. 137 (4), 636–638 (2004).
65. Martin DF, Parks DJ, Mellow SD et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol. 112 (12), 1531–1539 (1994).
66. Pepose JS, Newman C, Bach MC et al. Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir. Ophthalmology 94 (4), 414–424 (1987).
67. Jacobson MA, O’Donnell JJ, Brodie HR, Wofsy C, Mills J. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J. Med. Virol. 25 (3), 339–349 (1988).
68. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med. 326 (4), 213–220 (1992).
69. Hoffman VF, Skiest DJ. Therapeutic developments in cytomegalovirus retinitis. Expert Opin. Investig. Drugs 9 (2), 207–220 (2000).
70. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7 (3–4), 189–198 (1999).
71. AIDS Clinical Trials Group (ACTG). Studies of ocular complications of AIDS Foscarnet–Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin. Trials 13 (1), 22–39 (1992).
72. Studies of Ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. A randomized, controlled trial. Ann. Intern. Med. 126 (4), 264–274 (1997).
73. Palestine AG, Polis MA, De Smet MD et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115 (9), 665–673 (1991).
74. Spector SA, Weingeist T, Pollard RB et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J. Infect. Dis. 168 (3), 557–563 (1993).
75. Lalezari JP, Stagg RJ, Kuppermann BD et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 126 (4), 257–263 (1997).
76. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch. Intern. Med. 155 (1), 65–74 (1995).
77. Davidson M, Min YI, Holbrook JT et al. Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. AIDS 16 (5), 757–765 (2002).
78. Thorne JE, Jabs DA, Vitale S, Miller T, Dunn JP, Semba RD. Catheter complications in AIDS patients treated for cytomegalovirus retinitis. AIDS 12 (17), 2321–2327 (1998).
79. Spector SA, Busch DF, Follansbee S et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a Phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J. Infect. Dis. 171 (6), 1431–1437 (1995).
80. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 9 (5), 471–477 (1995).
81. Lalezari JP, Friedberg DN, Bissett J et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. J. Clin. Virol. 24 (1–2), 67–77 (2002).
82. Katlama C, Dohin E, Caumes E et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. J. Acquir. Immune Defic. Syndr. 5 (Suppl. 1), S18 –S24 (1992).
83. Lalezari JP, Drew WL, Glutzer E et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171 (4), 788–796 (1995).
84. Arevalo JF, Gonzalez C, Capparelli EV et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J. Infect. Dis. 172 (4), 951–956 (1995).
85. Kuppermann BD, Quiceno JI, Flores-Aguilar M et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J. Infect. Dis. 168 (6), 1506–1509 (1993).
86. Jabs DA, Wingard JR, de Bustros S, de Miranda P, Saral R, Santos GW. BW B759U for cytomegalovirus retinitis: intraocular drug penetration. Arch. Ophthalmol. 104 (10), 1436–1437 (1986).
87. Marx JL, Kapusta MA, Patel SS et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch. Ophthalmol. 114 (7), 815–820 (1996).
88. Kappel PJ, Charonis AC, Holland GN et al. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis. Ophthalmology 113 (4), 683, e681–e688 (2006).
89. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340 (14), 1063–1070 (1999).
90. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch. Ophthalmol. 107 (12), 1767–1772 (1989).
91. Cochereau-Massin I, Lehoang P, Lautier-Frau M et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 98 (9), 1348–1353 (1991).
92. Young SH, Morlet N, Heery S, Hollows FC, Coroneo MT. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med. J. Aust. 157 (6), 370–373 (1992).
93. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report. Ann. Intern. Med. 125 (2), 98–103 (1996).
94. Kirsch LS, Arevalo JF, De Clercq E et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 119 (4), 466–476 (1995).
95. Diaz-Llopis M, Espana E, Munoz G et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br. J. Ophthalmol. 78 (2), 120–124 (1994).
96. Studies of Ocular Complications of AIDS Research Group and The AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am. J. Ophthalmol. 131 (4), 457–467 (2001).
97. Whitcup SM, Fortin E, Lindblad AS et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 282 (17), 1633–1637 (1999).
98. + counts. Ophthalmology 105 (7), 1259–1264 (1998).
99. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am. J. Ophthalmol. 126 (6), 817–822 (1998).
100. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J. Infect. Dis. 177 (5), 1182–1187 (1998).
101. Tural C, Romeu J, Sirera G et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. 177 (4), 1080–1083 (1998).
102. Sklar PA, Agyemang AF, Monastra R et al. Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis. AIDS 18 (3), 567–569 (2004).
103. Curi AL, Muralha A, Muralha L, Pavesio C. Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy. Br. J. Ophthalmol. 85 (4), 471–473 (2001).
104. Jabs DA. Discontinuing anticytomegalovirus therapy in patients with cytomegalovirus retinitis and AIDS. Br. J. Ophthalmol. 85 (4), 381–382 (2001).
105. Macdonald JC, Karavellas MP, Torriani FJ et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology 107 (5), 877–881 (2000).
106. Jouan M, Saves M, Tubiana R et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15 (1), 23–31 (2001).
107. Berenguer J, Gonzalez J, Pulido F et al. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin. Infect. Dis. 34 (3), 394–397 (2002).
108. Torriani FJ, Freeman WR, Macdonald JC et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 14 (2), 173–180 (2000).
109. Nussenblatt RB, Lane HC. Human immunodeficiency virus disease: changing patterns of intraocular inflammation. Am. J. Ophthalmol. 125 (3), 374–382 (1998).
110. 6 cells/l following combination antiretroviral therapy including protease inhibitors. AIDS 11 (13), 1659–1660 (1997).
111. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm. Rep. 48 (RR-10), 1–59, 61–56 (1999).
112. Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin. Infect. Dis. 32 (5), 815–819 (2001).
113. Cassoux N, Bodaghi B, Fillet AM, Carcelain G, Katlama C, Lehoang P. Relapses of CMV retinitis after 2 years of highly active antiretroviral therapy. Br. J. Ophthalmol. 84 (10), 1203 (2000).
114. + T cell response. J. Clin. Virol. 26 (1), 95–100 (2003).
115. Song MK, Schrier RD, Smith IL, Plummer DJ, Freeman WR. Paradoxical activity of CMV retinitis in patients receiving highly active antiretroviral therapy. Retina 22 (3), 262–267 (2002).
116. + T cell counts and recurrent retinitis. J. Infect. Dis. 183 (8), 1285–1289 (2001).
117. + lymphocyte responses in HIV+ patients. Br. J. Ophthalmol. 82 (9), 988–990 (1998).
118. Jacobson MA, Zegans M, Pavan PR et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349 (9063), 1443–1445 (1997).
119. Whitcup SM, Cunningham ET Jr, Polis MA, Fortin E. Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy. Br. J. Ophthalmol. 82 (7), 845–846 (1998).
120. Chung H, Kim KH, Kim JG, Lee SY, Yoon YH. Retinal complications in patients with solid organ or bone marrow transplantations. Transplantation 83 (6), 694–699 (2007).
121. Bradfield YS, Kushner BJ, Gangnon RE. Ocular complications after organ and bone marrow transplantation in children. J. AAPOS 9 (5), 426–432 (2005).
122. Church J, Goyal S, Tyagi AK, Scott RA, Stavrou P. Cytomegalovirus retinitis in chronic lymphocytic leukaemia. Eye DOI: 10.1038/sj.eye.6702550 (2006) (Epub ahead of print).
123. Bertelmann E, Liekfeld A, Pleyer U, Hartmann C. Cytomegalovirus retinitis in Wegener’s granulomatosis: case report and review of the literature. Acta Ophthalmol. Scand. 83 (2), 258–261 (2005).
124. Haerter G, Manfras BJ, de Jong-Hesse Y et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor α antibody therapy for rheumatoid arthritis. Clin. Infect. Dis. 39 (9), e88 –e94 (2004).
125. Ishikawa K, Ando Y, Narita M, Shinjoh M, Iwasaki T. Cytomegalovirus retinitis during immunotherapy for common variable immunodeficiency. J. Infect. 44 (1), 55–56 (2002).
126. Witte T, Werwitzke S, Schmidt RE. CMV complications in common variable immunodeficiency. Immunobiology 202 (2), 194–198 (2000).
127. Cunningham E, Pepose J, Holland G. Cytomegalovirus infections of the retina. In: Retina. Ryan S (Ed.) Mosby, London, UK 1558–1575 (2001).
128. Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am. J. Ophthalmol. 143 (2), 334–335 (2007).
129. Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am. J. Ophthalmol. 140 (6), 1141–1143 (2005).
130. Delyfer MN, Rougier MB, Hubschman JP, Aouizerate F, Korobelnik JF. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol. Scand. (2007) (Epub ahead of print).
131. Coats DK, Demmler GJ, Paysse EA, Du LT, Libby C. Ophthalmologic findings in children with congenital cytomegalovirus infection. J. AAPOS 4 (2), 110–116 (2000).
132. Kuo IC, Kempen JH, Dunn JP, Vogelsang G, Jabs DA. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am. J. Ophthalmol. 138 (3), 338–346 (2004).
133. Luan FL, Chopra P, Park J, Norman S, Cibrik D, Ojo A. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. Transplant Proc. 38 (10), 3673–3675 (2006).
134. Fellay J, Venetz JP, Pacual M, Aubert JD, Seudoux C, Meylan PR. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am. J. Transplant. 5 (7), 1781–1782; author reply 1783 (2005).
135. Plummer DJ, Sample PA, Freeman WR. Visual dysfunction in HIV-positive patients without infectious retinopathy. AIDS Patient Care STDs 12 (3), 171–179 (1998).
136. Plummer DJ, Sample PA, Arevalo JF et al. Visual field loss in HIV-positive patients without infectious retinopathy. Am. J. Ophthalmol. 122 (4), 542–549 (1996).
137. Geier SA, Hammel G, Bogner JR, Kronawitter U, Berninger T, Goebel FD. HIV-related ocular microangiopathic syndrome and color contrast sensitivity. Invest. Ophthalmol. Vis. Sci. 35 (7), 3011–3021 (1994).
138. Latkany PA, Holopigian K, Lorenzo-Latkany M, Seiple W. Electroretinographic and psychophysical findings during early and late stages of human immunodeficiency virus infection and cytomegalovirus retinitis. Ophthalmology 104 (3), 445–453 (1997).